IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced inducement grants on March 26, 2026 of non-qualified stock options totaling 49,000 shares to two newly hired employees under the 2023 Inducement Plan.

The options carry an exercise price of $32.09 (closing price on grant date), a 10-year term, and vest over four years (25% after one year, then monthly over three years), subject to continued service.

Key Figures

Inducement options: 49,000 shares Exercise price: $32.09 per share Option term: 10 years +2 more

5 metrics

Inducement options 49,000 shares Granted to two newly hired employees under 2023 Inducement Plan

Exercise price $32.09 per share Equal to Nasdaq Global Select Market closing price on March 26, 2026

Option term 10 years Term of inducement stock options granted March 26, 2026

Initial vesting 25% Options vest on first anniversary of vesting commencement date

Remaining vesting period 3 years Remaining 75% vests in equal monthly installments thereafter

Market Reality Check

Price: $30.46 Vol: Volume 790,869 is at 0.81...

normal vol

$30.46 Last Close

Volume Volume 790,869 is at 0.81x the 20-day average of 978,209, indicating typical trading activity pre-announcement. normal

Technical Shares traded at $32.09, above the 200-day MA of $29.23 and about 18.3% below the $39.28 52-week high.

Peers on Argus

Pre-news, IDYA was up 2.23% while only one momentum peer, DNLI, showed a modest ...

1 Up

Pre-news, IDYA was up 2.23% while only one momentum peer, DNLI, showed a modest ~1.04% move up and other close peers had mixed performance, suggesting stock-specific factors dominated.

Historical Context

5 past events · Latest: Mar 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 18	AACR presentation plans	Positive	-2.8%	Announced three AACR 2026 poster presentations for multiple Phase 1 programs.
Mar 09	Phase 1 FPI IDE892	Positive	+5.7%	Reported first‑patient‑in for Phase 1 IDE892 and MTAP/CDKN2A pipeline updates.
Feb 27	Partner milestone IDE034	Positive	+2.6%	Biocytogen announced first dosing in IDE034 Phase 1 triggering $5M milestone.
Feb 27	Inducement option grants	Neutral	+0.9%	Granted 346,200 inducement stock options under 2023 Inducement Plan.
Feb 25	Phase 1 FPI IDE034	Positive	-1.3%	Announced first‑patient‑in for Phase 1 trial of bispecific ADC IDE034.

Pattern Detected

Recent clinically focused announcements often led to mixed reactions, with some positive trial milestones coinciding with negative next-day moves, while more routine administrative or grant-related news saw relatively small aligned moves.

Recent Company History

Over the past months, IDEAYA has reported multiple clinical milestones and partnership updates. Key events include first‑patient‑in for Phase 1 trials of IDE892 and IDE034, each triggering $5 million milestone payments to Biocytogen, and AACR 2026 presentation plans highlighting several Phase 1 programs. The company also issued prior inducement grants similar to today’s announcement on February 26, 2026. Price reactions have been mixed, with some positive clinical updates followed by gains and others by pullbacks, underscoring variable market responses to news flow.

Market Pulse Summary

This announcement details a small inducement grant of 49,000 stock options at an exercise price of $...

Analysis

This announcement details a small inducement grant of 49,000 stock options at an exercise price of $32.09, vesting over four years under Nasdaq Listing Rule 5635(c)(4). It follows earlier 2026 equity awards to senior executives and prior inducement grants, indicating consistent use of equity for talent recruitment and retention. Investors may track how such grants accumulate relative to total shares outstanding and focus primarily on upcoming clinical and financial milestones to gauge the broader equity story.

Key Terms

non-qualified stock options, Nasdaq Listing Rule 5635(c)(4)

2 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 49,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., March 27, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 26, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 49,000 shares of the Company's common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $32.09 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302726786.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What did IDEAYA (IDYA) grant on March 26, 2026 as inducement awards?

IDEAYA granted non-qualified stock options for an aggregate of 49,000 shares to two newly hired employees. According to the company, the awards were made under the 2023 Inducement Plan as material inducements to employment.

What is the exercise price and term of the IDYA inducement stock options?

The stock options carry an exercise price of $32.09, equal to the closing price on grant date, and have a 10-year term. According to the company, the price matches the Nasdaq closing price on March 26, 2026.

How do the IDEAYA inducement options vest for the new employees (IDYA)?

The options vest over four years: 25% vest on the first anniversary, then the remaining 75% vest in equal monthly installments over three years. According to the company, vesting is conditioned on continued service.

Under which plan were IDEAYA's (IDYA) inducement awards made and who is eligible?

Awards were made under the 2023 Inducement Plan, which is used exclusively for individuals not previously employed or after bona fide non-employment. According to the company, grants comply with Nasdaq Listing Rule 5635(c)(4).

Will IDEAYA's (IDYA) inducement option vesting be accelerated automatically?

No automatic acceleration was disclosed; vesting is tied to continued service on each vesting date. According to the company, the described schedule is 25% after one year and monthly thereafter for three years.